BioParity.UFO / UAP research

2 sources for “Preclinical study limitations”

Results

PaperS7610

Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity

Lu Cui, Shih-Yu Chen, Tristan Lerbs, Jin-Wook Lee, Pablo Domizi, Sydney Gordon, Yong-hun Kim, Garry Nolan, Paola Betancur, Gerlinde Wernig. ebi.ac.uk. June 3, 2020.

The authors report JUN-associated changes in lung fibroblasts and test mechanisms and interventions in engineered cultures and mouse models. Eleven end-stage cases and three cancer-resection controls define the human comparison. Preclinical findings, sampling biases and explicit toxicity cautions prevent claims of proven treatment benefit or safety in patients.

Complete supplied main text; bounded supplemental visuals
PaperS7583

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia

Jolanda Sarno, Angela M Savino, Chiara Buracchi, Chiara Palmi, Stefania Pinto, Cristina Bugarin, Astraea Jager, Silvia Bresolin, Ruth C Barber, Daniela Silvestri, Shai Israeli, Martin JS Dyer, Giovanni Cazzaniga, Garry P Nolan, Andrea Biondi, Kara L Davis, Giuseppe Gaipa. ebi.ac.uk. May 1, 2018.

A preclinical leukemia study reports signaling and cell-viability responses to SRC/ABL inhibition. Results vary across selected samples, cell models and treatment conditions. Negative findings, limited sample availability and statistical inconsistencies qualify the claims. The supplied main text and supplement are read; clinical effectiveness and UAP relevance are not established.

Supplied main text and supplement read; original main layout incomplete

A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach